Clinical Pharmacology & Toxicology Recent Publications

To obtain copies of these publications, please contact the Clinical Pharmacology and Toxicology Department on  (02) 8382 – 9184

 

1. Wong, C.; Kumar, S. S.; Graham, G. G.; Begg, E. J.; Chin, P. K.; Brett, J.; Ray, J. E.; Marriott, D. J.; Williams, K. W.; Day, R. O. Comparing dose prediction software used to manage gentamicin dosing. Intern Med J. 2013;43(5):519-25. Epub 2013/01/03.

2. Williams, C. M.; Maher, C. G.; Latimer, J.; McLachlan, A. J.; Hancock, M. J.; Day, R. O.; Billot, L.; Lin, C. W. PACE – the first placebo controlled trial of paracetamol for acute low back pain: statistical analysis plan. Trials. 2013;14:248.

3. Westbrook, J. I.; Baysari, M. T.; Li, L.; Burke, R.; Richardson, K.; Day, R. O. The safety of electronic prescribing: Rates, manifestations and mechanisms of system-related errors associated with two commercial systems in hospitals. J Am Med Inform Assoc. 2013;0:1-9.

4. Teo, C.; Baysari, M. T.; Day, R. Understanding compliance to an antibiotic prescribing policy: Perspectives of policymakers and prescribers. J Pharm Pract Res. 2013;43(1):32-6.

5. Ramasamy, S. N.; Korb-Wells, C. S.; Kannangara, D. R. W.; Smith, M. W. H.; Wang, N.; Roberts, D. M.; Graham, G. G.; Williams, K. M.; Day, R. O. Allopurinol hypersensitivity: A systematic review of all published cases, 1950 – 2012. Drug Saf. 2013;(Online first; 2013/07/20).

6. Perera, V.; Dolton, M. J.; McLachlan, A. J.; Carr, V. J.; Day, R. O. Pharmacometrics: An underutilised resource in Australian clinical research. The Medical Journal of Australia. 2013;(Accepted 15/8/13).

7. Mathieson, S.; Maher, C. G.; McLachlan, A. J.; Latimer, J.; Koes, B. W.; Hancock, M. J.; Harris, I.; Day, R. O.; Pik, J.; Jan, S.; Billot, L.; Lin, C. W. PRECISE – pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. Trials. 2013;14(1):213. Epub 2013/07/13.

8. Lipworth, W. L.; Kerridge, I. H.; Day, R. O. Formulating an Ethics Agenda for Drug Development, Regulation, and Utilization. Therapeutic Innovation & Regulatory Science. 2013;47(1):46-9.

9. Lewis, J. R. R.; Lipworth, W. L.; Kerridge, I. H.; Day, R. O. The economic evaluation of personalised oncology medicines: Ethical challenges. The Medical Journal of Australia. 2013;199(7):471-3.

10. Lee, P.; Day, R. O.; Greenfield, J.; Ho, K. Formoterol, a highly β2-selective agonist, increases energy expenditure and fat utilisation in men. International Journal of Obesity. 2013;37(4):593-7. Epub 2012/05/29.

11. Lee, M. H.; Stocker, S. L.; Williams, K. M.; Day, R. O. HLA-B*5801 should be used to screen for risk of Stevens-Johnson Syndrome (SJS) in family members of Han-Chinese patients commencing allopurinol therapy. J Rheumatol. 2013;40(1):96-7.

12. Kannangara, D. R. W.; Graham, G. G.; Williams, K. M.; Day, R. O. Hypouricemic Effects of Prednisone and Allopurinol: An Uneven Playing Field? Can J Cardiol. 2013. Epub 2013/07/13.

13. Jaensch, S. L.; Baysari, M. T.; Day, R. O.; Westbrook, J. I. Junior doctors’ prescribing work after-hours and the impact of computerized decision support. Int J Med Inform. 2013;(Accepted 30 June 2013).

14. Graham, G. G.; Kannangara, D. R. W.; Stocker, S. L.; Portek, I.; Pile, K. D.; Indraratna, P. L.; Datta, I.; Williams, K. M.; Day, R. O. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Brit J Clin Pharmacol. 2013;(Accepted 18th March, 2013).

15. Graham, G. G.; Day, R. O. Salicylates. In: Parnham MJ, editor. Encyclopedia of Inflammatory Diseases2013.

16. Graham, G. G.; Davies, M. J.; Day, R. O.; Mohamudally, A.; Scott, K. F. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacol. 2013:1-32. Epub 2013/05/30.

17. Ghinea, N.; Lipworth, W.; Kerridge, I.; Day, R. Overcoming entrenched disagreements. The case of misoprostol for post-partum haemorrhage. Developing World Bioethics. 2013;(Accepted 16th June, 2013).

18. Gallego, B.; Runciman, W. B.; Perez-Concha, O.; Liaw, S.-T.; Day, R. O.; Dunn, A. G.; Coeira, E. The management of severe hypertension in Australian general practice. BMC Health Services Research. 2013.

19. Duong, J. K.; Kumar, S. S.; Kirkpatrick, C. M.; Greenup, L. C.; Arora, M.; Lee, T. C.; Timmins, P.; Graham, G. G.; Furlong, T. J.; Greenfield, J. R.; Williams, K. M.; Day, R. O. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes: Simulation of doses according to renal function. Clin Pharmacokinet. 2013. Epub 2013 Mar 9.

20. Duong, J. K.; Furlong, T. J.; Roberts, D. M.; Graham, G. G.; Greenfield, J. R.; Williams, K. M.; Day, R. O. The role of metformin in metformin-associated lactic acidosis (MALA): Case series and formulation of a model of pathogenesis. Drug Saf. 2013. Epub 2013/04/03.

21. Day, R. O.; Williams, K. M.; Graham, G. G. Urate-lowering therapy: uricosurics. Gout: Future Medicine Ltd; 2013. p. 174-88.

22. Day, R. O.; Lee, M. H.; Graham, G. G.; Williams, K. M. Benzbromarone: Availability for general prescribing in New Zealand. The New Zealand Medical Journal. 2013;(Accepted 3/9/13).

23. Day, R. O.; Graham, G. G.; Williams, K. M. Propionic acid derivative drugs (Profens). In: Parnham MJ, editor. Encyclopedia of Inflammatory Diseases2013.

24. Day, R. O.; Graham, G. G. Non-steroidal anti-inflammatory drugs. In: Parnham MJ, editor. Encyclopedia of Inflammatory Diseases2013.

25. Day, R. O.; Graham, G. G. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ (Clinical research ed). 2013;346:f3195.

26. Carmichael, S. J.; Day, R. O.; Tett, S. E. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J. 2013;43(5):547-53.

27. Brett, J.; Lam, V.; Baysari, M. T.; Milder, T.; Killen, L.; Chau, A. M. T.; McMullan, B.; Harkness, J.; Marriot, D.; Day, R. O. Use of pneumonia severity scores and antibiotic prescribing in the management of community-acquired pneumonia at an Australian tertiary teaching hospital. J Pharm Pract Res. 2013;43(2):97-100.

28. Brett, J.; Chong, O.; Graham, G. G.; Ray, J. E.; Marriott, D.; Williams, K. M.; Day, R. O. Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients. Ther Drug Monit. 2013;35(1):133-6. Epub 2012/11/29.

29. Baysari, M. T.; Westbrook, J. I.; Egan, E.; Day, R. O. Identification of strategies to reduce computerized alerts in an electronic prescribing system using a Delphi approach. In: Lehmann CU, Ammenwerth E, Nøhr C, editors. Studies in health technology and informatics: IMIA and IOS Press; 2013. p. 8-12.

30. Arabadzhiyska, P.; Baysari, M. T.; Walter, S.; Day, R. O.; Westbrook, J. Shedding light on junior doctors’ work practices after hours. Intern Med J. 2013;(Accepted 18th June, 2013).

31. Westbrook, J. I.; Reckmann, M.; Li, L.; Runciman, W. B.; Burke, R.; Lo, C.; Baysari, M. T.; Braithwaite, J.; Day, R. O. Effects of two commercial electronic prescribing systems on prescribing error rates in hospital in-patients: A before and after study. PLoS medicine. 2012;9(1):e1001164. Epub 2012/02/04.

32. Stocker, S. L.; McLachlan, A. J.; Savic, R. M.; Kirkpatrick, C. M.; Graham, G. G.; Williams, K. M.; Day, R. O. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012;74(3):477-89.

33. Runciman, W. B.; Hunt, T. D.; Hannaford, N. A.; Hibbert, P. D.; Westbrook, J. I.; Coiera, E. W.; Day, R. O.; Hindmarsh, D. M.; McGlynn, E. A.; Braithwaite, J. CareTrack: Assessing the appropriateness of health care delivery in Australia. Med J Aust. 2012;197(2):100-5. Epub 2012/07/17.

34. Runciman, W. B.; Coiera, E. W.; Day, R. O.; Hannaford, N. A.; Hibbert, P. D.; Hunt, T. D.; Westbrook, J. I.; Braithwaite, J. Towards the delivery of appropriate health care in Australia. Med J Aust. 2012;197(2):78-81. Epub 2012/07/17.

35. Lipworth, W. L.; Kerridge, I. H.; Day, R. O. Wrong questions, wrong answers? Are we getting the drugs we need? Clin Pharmacol Ther. 2012;91(3):367-9. Epub 2012/02/22.

36. Lipworth, W. L.; Kerridge, I.; Day, R. O. Time for the Pharmaceutical Benefits Advisory Committee to set its own agenda. Med J Aust. 2012;196(6):374-5. Epub 2012/04/05.

37. Lipworth, W.; Kerridge, I.; Little, M.; Day, R. Evidence and desperation in off-label prescribing: Recombinant factor VIIa. BMJ (Clinical research ed). 2012;344:d7926.

38. Lipworth, W.; Kerridge, I.; Day, R. O.; Ho, K. Drug policy at the margins: The case of growth hormone replacement for adults with severe growth hormone deficiency. Med J Aust. 2012;197(4):204-5.

39. Lee, M. H.; Stocker, S. L.; Anderson, J.; Phillips, E. J.; Nolan, D.; Williams, K. M.; Graham, G. G.; Sullivan, J. R.; Day, R. O. Initiating allopurinol therapy: Do we need to know the patient’s human leucocyte antigen status? Intern Med J. 2012;42(4):411-6. Epub 2011/07/28.

40. Kannangara, D. R.; Roberts, D. M.; Furlong, T. J.; Graham, G. G.; Williams, K. M.; Day, R. O. Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease. Br J Clin Pharmacol. 2012;73(5):828-9. Epub 2011/11/22.

41. Kannangara, D. R.; Ramasamy, S. N.; Indraratna, P. L.; Stocker, S. L.; Graham, G. G.; Jones, G.; Portek, I.; Williams, K. M.; Day, R. O. Fractional clearance of urate: Validation of measurement in spot urine samples in healthy subjects and gouty patients. Arthritis Res Ther. 2012;14(4):R189. Epub 2012/08/21.

42. Hunt, T. D.; Ramanathan, S. A.; Hannaford, N. A.; Hibbert, P. D.; Braithwaite, J.; Coiera, E.; Day, R. O.; Westbrook, J. I.; Runciman, W. B. CareTrack Australia: Assessing the appropriateness of adult healthcare: Protocol for a retrospective medical record review. BMJ open. 2012;2:e000665. Epub 2012/01/21.

43. Ghinea, N.; Lipworth, W.; Kerridge, I.; Day, R. No evidence or no alternative? Taking responsibility for off-label prescribing. Intern Med J. 2012;42(3):247-51. Epub 2012/03/22.

44. Fransen, M.; Agaliotis, M.; Nairn, L.; Votrubec, M.; Bridgett, L.; Su, S.; Jan, S.; March, L.; Edmonds, J.; Bridges-Webb, C.; Norton, R.; Woodward, M.; Day, R. Glucosamine and Chondroitin for Knee Osteoarthritis: A Double-Blind Randomised Placebo-Controlled Clinical Trial Evaluating Single and Combination Regimens. ACR/ARHP Annual Meeting2012.

45. Duong, J. K.; Roberts, D. M.; Furlong, T. J.; Kumar, S. S.; Greenfield, J. R.; Kirkpatrick, C. M.; Graham, G. G.; Williams, K. M.; Day, R. O. Metformin therapy in patients with chronic kidney disease. Diabetes, obesity & metabolism. 2012;14(10):963-5. Epub 2012/05/09.

46. Dunn, A. G.; Day, R. O.; Mandl, K. D.; Coiera, E. Learning from hackers: Open-source clinical trials. Science translational medicine. 2012;4(132):132cm5. Epub 2012/05/04.

47. Dunn, A. G.; Bourgeois, F. T.; Murthy, S.; Mandl, K. D.; Day, R. O.; Coiera, E. The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics. Clin Pharmacol Ther. 2012;91(4):685-91. Epub 2012/03/02.

48. Dunn, A.; Braithwaite, J.; Gallego, B.; Day, R.; Runciman, W.; Coiera, E. Nation-scale adoption of new medicines by doctors: An application of the Bass diffusion model. BMC Health Services Research. 2012;12(1):248.

49. Day, R. O.; Kannangara, D. R. W.; Hayes, J. M.; Furlong, T. J. Successful use of allopurinol in a patient on dialysis. BMJ Case Reports. 2012:10.1136/bcr.02.2012.5814, Published XXX.

50. Baysari, M. T.; Westbrook, J. I.; Day, R. O. Understanding doctors’ perceptions of their prescribing competency and the value they ascribe to an electronic prescribing system. Studies in health technology and informatics. 2012;178:1-6. Epub 2012/07/17.

51. Baysari, M. T.; Tang, T.; Brett, J.; Day, R. O. Implementation of revised aminoglycoside guidelines: Australian hospitals ‘left in the lurch’. Journal of Pharmacy Practice and Research. 2012;42(3):178-9.

52. Baysari, M. T.; Reckmann, M. H.; Li, L.; Day, R. O.; Westbrook, J. I. Failure to utilize functions of an electronic prescribing system and the subsequent generation of ‘technically preventable’ computerized alerts. J Am Med Inform Assoc. 2012;19:1003-10. Epub 2012/06/28.

53. Baysari, M. T.; Day, R. O.; Westbrook, J. I. Consistency or efficiency? A dilemma for designers. J Am Med Inform Assoc. 2012;19:1119-20.

54. Wang, N.; Lipworth, W. L.; Ritchie, J. E.; Williams, K. M.; Day, R. O. Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines. Intern Med J. 2011;41(4):314-20. Epub 2010/04/21.

55. Stocker, S. L.; Graham, G. G.; McLachlan, A. J.; Williams, K. M.; Day, R. O. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38(5):904-10. Epub 2011/02/03.

56. Smith, M. W.; Roberts, D. M.; Ritson, S. M.; Day, R. O. Death and morbidity from supratherapeutic dosing of colchicine. Med J Aust. 2011;194(11):612-3. Epub 2011/06/08.

57. Roberts, D. M.; Smith, M. W.; McMullan, B. J.; Sevastos, J.; Day, R. O. Acute kidney injury due to crystalluria following acute valacyclovir overdose. Kidney Int. 2011;79(5):574. Epub 2011/02/16.

58. Roberts, D. M.; Smith, M. W.; Gopalakrishnan, M.; Whittaker, G.; Day, R. O. Extreme gamma-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med. 2011;58(1):83-5. Epub 2011/03/26.

59. Roberts, D. M.; Chau, A. M.; Nair, P.; Day, R. O. Enhanced elimination of phenobarbital using charcoal haemoperfusion in a patient with severe poisoning. British journal of anaesthesia. 2011;107(5):820-1. Epub 2011/10/15.

60. Pile, K. D.; Graham, G. G.; Mahler, S. M.; Day, R. O. Disease Modifying Antirheumatic Drugs. In: Nijkamp FP, Parnham MJ, editors. Principles of Immunopharmacology. 3rd ed. Basel, Switzerland: Birkhauser Publishing; 2011. p. 585-619.

61. Ng, D. Y.; Stocker, S. L.; Graham, G. G.; Williams, K. M.; Day, R. O. Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers. Eur J Clin Pharmacol. 2011;67:709-13. Epub 2010/12/25.

62. Milder, T. Y.; Williams, K. M.; Ritchie, J. E.; Lipworth, W. L.; Day, R. O. Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: engagement with information and perceptions of risk. Age Ageing. 2011;40(2):254-9. Epub 2010/12/29.

63. Milder, T. Y.; Lipworth, W. L.; Williams, K. M.; Ritchie, J. E.; Day, R. O. “It looks after me”: How older patients make decisions about analgesics for osteoarthritis. Arthritis care & research. 2011;63(9):1280-6. Epub 2011/06/15.

64. Lipworth, W. L.; Wodak, A. D.; Haber, P. S.; Day, R. O. Why is disulfiram not on the PBS? Med J Aust. 2011;195(7):371-2. Epub 2011/10/08.

65. Lipworth, W.; Kerridge, I.; Brett, J.; Day, R. How clinical and research failures lead to suboptimal prescribing: The example of chronic gout. BMJ (Clinical research ed). 2011;343:d7459. Epub 2011/12/03.

66. Lee, P.; Kengne, A. P.; Greenfield, J. R.; Day, R. O.; Chalmers, J.; Ho, K. K. Metabolic sequelae of beta-blocker therapy: Weighing in on the obesity epidemic? Int J Obes (Lond). 2011;35(11):1395-403. Epub 2011/02/8.

67. Inam, S.; Lipworth, W. L.; Kerridge, I. H.; Day, R. O. Rethinking the discordance between guidelines and practice in rheumatoid arthritis treatment. Med J Aust. 2011;195(8):446-7. Epub 2011/10/19.

68. Harvey, K. J.; Day, R. O.; Campbell, W. G.; Lipworth, W. Saving money on the PBS: Ranibizumab or bevacizumab for neovascular macular degeneration? Med J Aust. 2011;194(11):567-8. Epub 2011/06/08.

69. Greenfield, J.; Graham, G.; Day, R. The use of metformin in diabetic patients with renal impairment. Geriatric Medicine in General Practice. 2011;8:26, 8-9.

70. Graham, G. G.; Punt, J.; Arora, M.; Day, R. O.; Doogue, M. P.; Duong, J. K.; Furlong, T. J.; Greenfield, J. R.; Greenup, L. C.; Kirkpatrick, C. M.; Ray, J. E.; Timmins, P.; Williams, K. M. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98. Epub 2011/01/19.

71. Day, R. O.; Roffe, D. J.; Richardson, K. L.; Baysari, M. T.; Brennan, N. J.; Beveridge, S.; Melocco, T.; Ainge, J.; Westbrook, J. I. Implementing electronic medication management at an Australian teaching hospital. Med J Aust. 2011;195(9):498-502. Epub 2011/11/09.

72. Day, R.; Quinn, D.; Williams, K.; Handel, M.; Brooks, P. Connective tissue and bone disorders. 2011.

73. Day, R.; Lipworth, W.; Kerridge, I. Death of the ‘blockbuster’ and ‘pivotal’ clinical trial: Rethinking the drug development process. J Pharm Pract Res. 2011;41(2):94-6.

74. Carney, S. L.; Gazarian, M.; Denholm, J. T.; Reith, D. M.; Penhall, R. K.; Jenkins, C. R.; Wilhelm, K. A.; Komesaroff, P. A.; Osborn, M. M.; Day, R. O. What’s in a name? Brand name confusion and generic medicines. Med J Aust. 2011;195(11-12):650-1. Epub 2011/12/17.

75. Brett, J.; Beresford, R.; Sevastos, J.; Day, R. Neem extract poisoning as a cause of renal tubular acidosis. J Clinic Toxicol. 2011;1(3):112.

76. Bombardier, C.; Laine, L.; Day, R.; Hawkey, C. J.; Hochberg, M. C.; Schnitzer, T. J. Rofecoxib and clinically significant gastrointestinal events. Am J Med Sci. 2011;342(5):438-9. Epub 2011/10/28.

77. Baysari, M. T.; Westbrook, J. I.; Richardson, K. L.; Day, R. O. The influence of computerized decision support on prescribing during ward-rounds: Are the decision-makers targeted? J Am Med Inform Assoc. 2011;18(6):754-9. Epub 2011/06/17.

78. Baysari, M. T.; Westbrook, J.; Braithwaite, J.; Day, R. O. The role of computerized decision support in reducing errors in selecting medicines for prescription: narrative review. Drug Saf. 2011;34(4):289-98. Epub 2011/03/23.

79. Baysari, M.; Westbrook, J.; Day, R. Medication decision-making on hospital ward-rounds. In: Moen A, Andersen SK, Aarts J, Hurlen P, editors. Studies in health technology and informatics. 2011/09/07 ed. Amsterdam: IOS Press; 2011. p. 935-9.

80. Williams, C. M.; Latimer, J.; Maher, C. G.; McLachlan, A. J.; Cooper, C. W.; Hancock, M. J.; Day, R. O.; McAuley, J. H.; Lin, C. W. PACE–the first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskelet Disord. 2010;11:169. Epub 2010/07/24.

81. Westbrook, J. I.; Woods, A.; Rob, M. I.; Dunsmuir, W. T.; Day, R. O. Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med. 2010;170(8):683-90. Epub 2010/04/28.

82. Stocker, S. L.; Franklin, M. E.; Anderson, J. M.; Pillans, P. I.; Williams, K. M.; McLachlan, A. J.; Day, R. O.; Taylor, P. J. Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(25):2363-8. Epub 2010/08/13.

83. Standfield, L.; Norris, S.; Harvey, C.; Elliot, L.; Riordan, J.; Hall, S.; Day, R.; Nash, P.; Thirunavukkarasu, K.; Robertson, J.; Palmer, T. Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study. Clin Ther. 2010;32(7):1329-42. Epub 2010/08/04.

84. Palmer, H.; Graham, G.; Williams, K.; Day, R. A risk-benefit assessment of paracetamol (acetaminophen) combined with caffeine. Pain Med. 2010;11(6):951-65. Epub 2010/07/14.

85. Magrabi, F.; Li, S. Y.; Day, R. O.; Coiera, E. Errors and electronic prescribing: a controlled laboratory study to examine task complexity and interruption effects. J Am Med Inform Assoc. 2010;17(5):575-83. Epub 2010/09/08.

86. Lu, C. Y.; Lu, V. H.; Goldberg, I.; Day, R. O. Towards integrated care: Australia’s new model of care for patients with glaucoma. Med J Aust. 2010;193(4):200-1. Epub 2010/08/18.

87. Indraratna, P. L.; Stocker, S. L.; Williams, K. M.; Graham, G. G.; Jones, G.; Day, R. O. A proposal for identifying the low renal uric acid clearance phenotype. Arthritis Res Ther. 2010;12(6):149. Epub 2010/12/18.

88. Graham, G. G.; Day, R. O.; Graudins, A.; Mohamudally, A. FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? Inflammopharmacology. 2010;18(2):47-55. Epub 2010/03/10.

89. Day, R. O.; Liauw, W.; Tozer, L. M.; McElduff, P.; Beckett, R. J.; Williams, K. M. A double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenopausal women. BMC Res Notes. 2010;3:180. Epub 2010/06/29.

90. Day, R. O.; Graham, G. G. Codeine —is it too risky? . Med J Aus. 2010.

91. Carter, S. M.; Samuel, G. N.; Kerridge, I.; Day, R.; Ankeny, R. A.; Jordens, C. F. C.; Komesaroff, P. Beyond rhetoric in debates about the ethics of marketing prescription medicines to consumers: The importance of vulnerability in people, situations, and relationships. AJOB Primary Research. 2010;1(1):11-21.

92. Abdul, M. I.; Jiang, X.; Williams, K. M.; Day, R. O.; Roufogalis, B. D.; Liauw, W. S.; Xu, H.; Matthias, A.; Lehmann, R. P.; McLachlan, A. J. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol. 2010;69(5):508-15. Epub 2010/06/25.

 

.